Investors pummeled AbbVie (ABBV) stock Wednesday after the company delivered a fourth-quarter sales beat that came largely on the back of still-declining Humira sales. Once key to AbbVie’s top line, Humira sales have now spent years under biosimilar pressure, forcing AbbVie to turn to its other immunology drugs for renewed growth. But Humira sales beat expectations by 29%, or $282…
